Lobe Sciences Ltd. (LOBE.CN)
| Previous Close | 0.0250 |
| Open | 0.0150 |
| Bid | 0.0000 x N/A |
| Ask | 0.0000 x N/A |
| Day's Range | 0.0150 - 0.0150 |
| 52 Week Range | 0.0100 - 0.0400 |
| Volume | |
| Avg. Volume | 33,670 |
| Market Cap | 1.187M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Business Wire
Lobe Sciences Provides Company Review of 2023
VANCOUVER, British Columbia, January 08, 2024--Lobe Sciences Ltd. (OTCQB: LOBEF) (CSE: LOBE) ("Lobe" or the "Company"), a biopharmaceutical company focused on developing transformative medicines to treat rare diseases today provided an update from the Company on its progress and achievements in 2023.
- Business Wire
Lobe Sciences Provides Update on L-130 Clinical Program
VANCOUVER, British Columbia, December 07, 2023--Lobe Sciences Ltd. (OTCQB: LOBEF) (CSE: LOBE) ("Lobe" or the "Company"), a biopharmaceutical company focused on developing transformative medicines to treat rare diseases today provided an update from the Company’s lead clinical program, L-130, a proprietary stabilized psilocin conjugate drug candidate. The Phase 1 study (NCT06035900) was an open label clinical trial in 10 normal and healthy individuals designed to determine the safety and pharmaco
- Business Wire
Lobe Sciences Provides Update on L-130 Oral Psilocin Compound
VANCOUVER, British Columbia, December 05, 2023--Lobe Sciences Reports 12 Months Stability for Lead Psilocin Drug Candidate (L-130).
